---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-25-000045"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:28:39.896475+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials

## Summary
- Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.
- Cash & short-term investments $24.1M; runway extended into late 2027 beyond key data readouts.
- Initiating Phase 2 KLARITY trial for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa); first patient enrollment expected Q2 2025.
- Received $1.8M in reimbursed Q4 2024 R&D expenses from Laboratoires Théa; total $5.6M since collaboration began.
- R&D expenses $2.5M (up from $1.7M) due to clinical trial activities; G&A $1.5M up from $1.3M.

## SEC filing metadata
- accession: 0001372514-25-000045
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/0001372514-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/kprx-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-25-000045
- JSON: https://secwatch.observer/filing/0001372514-25-000045.json
- Plain text: https://secwatch.observer/filing/0001372514-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.